Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders

3)-6) (canceled)

7) A method of stabilizing a complement-mediated ocular neovascularization disorder comprising administering an anti-complement aptamer to a subject in need thereof in an amount sufficient to stabilize the complement-mediated ocular neovascularization disorder.

9)-11) (canceled)

16)-20) (canceled)

21) A method of preventing a clinical complement-mediated ocular neovascularization disorder in a subject comprising administering an anti-complement aptamer to a subject in need thereof, in an amount sufficient to prevent a clinical symptom of the complement-mediated ocular neovascularization disorder.

23)-25) (canceled)

30) The method of claim of 21, wherein the anti-complement aptamer is administered in an amount sufficient to prevent a substantial increase in the level of retinal vessel density in the subject relative to the subject's retinal vessel density level upon anti-complement administration.

32)-33) (canceled)

38) The method of claim 32, wherein the C5 binding aptamer is ARC186, ARC187, ARC1905.

40)-41) (canceled)

44) (canceled)

47) A method of treating a C5, C5a and/or C5b-9 mediated ocular disorder, the method comprising the step of administering an anti-C5 agent to a subject in need thereof in an amount sufficient to treat the ocular disorder.

50) (canceled)

51) A method of stabilizing a C5, C5a and/or C5b-9 mediated ocular neovascularization disorder comprising administering an anti-C5 agent to a subject in need thereof in an amount sufficient to stabilize the C5, C5a and/or C5b-9 mediated ocular neovascularization disorder.

53)-54) (canceled)

59)-62) (canceled)

63) A method of preventing a clinical C5, C5a and/or C5b-9 mediated ocular neovascularization disorder in a subject comprising administering an anti-C5 agent to a subject, the method comprising the step of administering the anti-C5 agent to the subject in an amount sufficient to prevent a clinical symptom of the C5, C5a and/or C5b-9 mediated ocular neovascularization disorder.

65)-66) (canceled)

71) The method of claim of 63, wherein the anti-C5 agent is administered in an amount sufficient to prevent a substantial increase in the level of retinal vessel density in the subject relative to the subject's retinal vessel density level upon anti-C5 agent administration.